These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8282047)

  • 21. Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery.
    Kim YD; Foegh ML; Wallace RB; Ng L; Ahmed SW; Katz NM; Siegelman R; Franco K; Douglas F; Ku E
    Circulation; 1988 Sep; 78(3 Pt 2):I44-50. PubMed ID: 3409518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasal administration of retinal antigens maintains immunosuppression of uveoretinitis in cyclosporin-A-treated Lewis rats: future treatment of endogenous posterior uveoretinitis?
    Kreutzer B; Laliotou B; Cheng YF; Liversidge J; Forrester JV; Dick AD
    Eye (Lond); 1997; 11 ( Pt 4)():445-52. PubMed ID: 9425406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
    Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oligopeptides of three to five residues derived from uveitopathogenic sites of retinal S-antigen induce experimental autoimmune uveitis (EAU) in Lewis rats.
    Sunil S; Eto K; Singh VK; Shinohara T
    Cell Immunol; 1993 Apr; 148(1):198-207. PubMed ID: 8495487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High mobility group box protein-1 in experimental autoimmune uveoretinitis.
    Watanabe T; Keino H; Sato Y; Kudo A; Kawakami H; Okada AA
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2283-90. PubMed ID: 19151394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis.
    Prendergast RA; Iliff CE; Coskuncan NM; Caspi RR; Sartani G; Tarrant TK; Lutty GA; McLeod DS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):754-62. PubMed ID: 9538882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis.
    Longhofer SL; Frisbie DD; Johnson HC; Culham CA; Cooley AJ; Schultz KT; Grauer GF
    Am J Vet Res; 1991 Mar; 52(3):480-7. PubMed ID: 1827969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats.
    Ramanathan S; de Kozak Y; Saoudi A; Goureau O; Van der Meide PH; Druet P; Bellon B
    J Immunol; 1996 Sep; 157(5):2209-15. PubMed ID: 8757348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis.
    Dick AD; Cheng YF; Liversidge J; Forrester JV
    Immunology; 1994 Aug; 82(4):625-31. PubMed ID: 7835927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Protective effect of thromboxane A2 synthetase inhibitor (trapidil) on acutely-induced cerebral ischemia].
    Katayama Y; Shimizu J; Memezawa H; Minamisawa H; Suzuki S; Sugimoto S; Terashi A
    No To Shinkei; 1986 Oct; 38(10):925-31. PubMed ID: 3790357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of experimental autoimmune uveoretinitis with anti-macrophage migration inhibitory factor antibodies.
    Kitaichi N; Matsuda A; Kotake S; Namba K; Tagawa Y; Sasamoto Y; Ogasawara K; Iwabuchi K; Onoé K; Matsuda H; Nishihira J
    Curr Eye Res; 2000 Feb; 20(2):109-14. PubMed ID: 10617911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody.
    Zhang R; Qian J; Guo J; Yuan YF; Xue K
    Curr Eye Res; 2009 Apr; 34(4):297-303. PubMed ID: 19373578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H; Phillips GR; Dragon G; Lefer AM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate.
    Kitamei H; Iwabuchi K; Namba K; Yoshida K; Yanagawa Y; Kitaichi N; Kitamura M; Ohno S; Onoé K
    J Leukoc Biol; 2006 Jun; 79(6):1193-201. PubMed ID: 16574770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
    Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
    Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the thromboxane synthesis inhibitor CGS-12970 on experimental acute renal allograft rejection.
    Mangino MJ; Brunt EM; Von Doersten P; Anderson CB
    J Pharmacol Exp Ther; 1989 Jan; 248(1):23-8. PubMed ID: 2643702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experimental autoimmune uveitis and retinitis induced by S-antigen immunization].
    Misiuk-Hojło M; Ruiz-Moreno J; Thillaye B; de Kozak Y
    Klin Oczna; 1993; 95(3-4):101-4. PubMed ID: 8377430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.
    Longhofer SL; Johnson HC; Culham CA; Schultz KT; Grauer GF
    Am J Vet Res; 1990 Nov; 51(11):1746-50. PubMed ID: 2240799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.